Real-world management of hyperphosphataemia with sucroferric oxyhydroxide : The VELREAL multicentre study
Navarro-González, Juan F. (ERA-EDTA Working Group on CKD-MBD)
Arenas Jimenez, Maria Dolores (Hospital del Mar (Barcelona, Catalunya))
Henríquez-Palop, Fernando (Centro de Diálisis Avericum Norte)
Lloret, Maria Jesus (Institut d'Investigació Biomèdica Sant Pau)
Molina, Pablo (Hospital Universitari Doctor Peset (València))
Ríos Moreno, Francisco (Centro Diálisis San Luciano)
Macia-Lagier, María Asunción (Servicio de Nefrología. Hospital General de la Palma)
Espinel, Laura (Servicio de Nefrología. Hospital Universitario de Getafe)
Sánchez, Emilio (Servicio de Nefrología. Hospital Universitario de Cabueñes)
Lago, Mar (Servicio de Nefrología. Complejo Hospitalario Universitario Insular)
Crespo, Antonio (Servicio de Nefrología. Hospital Marina Baixa)
Bover, Jordi (Institut d'Investigació Biomèdica Sant Pau)

Data:	2021
Resum:	Background. The efficacy and safety of sucroferric oxyhydroxide (SO) have been reported in clinical trials. However, real-life data are scarce. This study presents data on the use, efficacy and safety of SO in real clinical practice. Methods. We performed a retrospective multicentre study, without any influence on the prescription decisions, that included 220 patients from 11 Spanish centres. Demographic, treatment, analytical and nutritional parameters and adherence, side effects and dropout rates were collected during 6 months. Results. SO was initiated due to inadequate control of serum phosphate (P) in 70% of participants and in 24. 5% to reduce the number of tablets. Monotherapy with SO increased from 44% to 74. 1%, with a reduction in the average daily number of sachets/tablets from six to two. Serum P decreased by 20% (4. 661. 2 versus 5. 861. 3 mg/dL; P<0. 001), with a significant reduction in intact parathyroid hormone levels (P<0. 01). The percentage of patients with adequate serum P control at threshold levels of 5 and 4. 5 mg/dL increased by 45. 4% and 35. 9%, respectively. Serum ferritin was not modified, while the transferrin saturation index increased significantly (P=0. 04). Serum albumin and normalized protein catabolic rate, when normalized by serum P, increased, averaging 37% and 39%, respectively (P<0. 001). Adherent patients increased from 28. 2% to 52. 7%. Adverse effects were reported by 14. 1% of participants, with abandonment of treatment in 9. 5%. Conclusions. The use of SO in real-life results in better control of serum P, a reduction in the number of tablets and an improvement in therapeutic adherence. In addition, it may be beneficial with regards to secondary hyperparathyroidism and nutritional status.
Nota:	Altres ajuts: Vifor Pharma España S.L.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Haemodialysis ; Hyperphosphataemia ; Nutritional status ; Sucorferric oxyhydroxide ; Therapeutic adherence
Publicat a:	Clinical Kidney Journal, Vol. 14 Núm. 2 (january 2021) , p. 681-687, ISSN 2048-8513

DOI: 10.1093/ckj/sfaa226
PMID: 33626111

7 p, 586.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats